CD4+CD8+ T cells are increased in urologic cancers patients and found to be high type-2 cytokine producers favoring a Th2 response in vitro while inhibiting Th1 cells known to play a crucial role in anti-tumor immunity (Bohner et al. 2019). Here, CD8A is linked to neoplasm.